Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols (France)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

194 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Study Completion Date

2005-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the effect on cholesterolemia profile of a low fat fermented milk enriched with plant sterol after 3 and 6 weeks of daily consumption in mildly hypercholesterolemic people treated or not by statins.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of the Consumption of a Fermented Dairy Product Enriched With Plant Sterols

NCT01521156

Mild Hypercholesterolemic Subjects

COMPLETED NA

Pilot Study in the Cholesterol Absorption Reduction After Consumption of Low-fat, Drinkable Fermented Milk Enriched With Plant Sterols

NCT01571869

Mildly Hypercholesterolemic Subjects

COMPLETED NA

Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols (Italy)

NCT01574482

Mildly Hypercholesterolemic Subjects

COMPLETED NA

Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols

NCT01340287

Hypercholesterolemia

COMPLETED NA

Effects of Fermented Milk Product Enriched With Plant Sterols and Policosanols in Mild Hypercholesterolaemic Adults

NCT01571882

Mildly Hypercholesterolemic Subjects

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mildly Hypercholesterolemic Subjects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1 = Tested product

Group Type ACTIVE_COMPARATOR

1-Low fat fermented dairy product enriched with plant sterol esters (0,8 g equivalent as free sterols) (test)

Intervention Type OTHER

1 = Intervention 1 (2 test products / day)

2 = Control product

Group Type PLACEBO_COMPARATOR

2-Low fat fermented dairy product (control)

Intervention Type OTHER

2 = Intervention 2 (2 control products/day)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1-Low fat fermented dairy product enriched with plant sterol esters (0,8 g equivalent as free sterols) (test)

1 = Intervention 1 (2 test products / day)

Intervention Type OTHER

2-Low fat fermented dairy product (control)

2 = Intervention 2 (2 control products/day)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male and female aged 18-75 years; BMI between 19 and 30 kg/m2 , LDL-cholesterol plasma level between 130 mg/dL to 190 mg/dL (bounds included) with or without statin monotherapy and without any other hypocholesterolemic treatment, accepting to follow the AFSSAPS dietary recommendations for hypercholesterolemic patients, affiliated to a health coverage system, agreeing to a written informed consent

Exclusion Criteria

* Subject with plasma triglycerides (TG) levels\>250 mg/dL, with any cardiovascular event in the last 6 months, taking any hypocholesterolemic treatment) other than statin in monotherapy, Diabetic (type I and type II), receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters, with any acute or chronic disease which could impact on results of the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes